Effective treatment of house metastatic prostate cancer by low electric field enhanced chemotherapy

Prostate

Volumn 66, Issue 15, 2006, Pages 1620-1630

  Plotnikov, Alexander ^a   Niego, Be'eri ^a   Ophir, Rachel ^a   Korenstein, Rafi ^a   Keisari, Yona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemotherapy; Electrostimulation; Immunostimulation; Low electric field; Prostate cancer

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL LINE; CONTROLLED STUDY; DRUG UPTAKE; ELECTRIC FIELD; ELECTROSTIMULATION; HISTOPATHOLOGY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW ELECTRIC FIELD CANCER TREATMENT ENHANCED CHEMOTHERAPY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; ELECTROCHEMOTHERAPY; ELECTROPORATION; MALE; MORTALITY; PATHOLOGY; PROSTATE TUMOR; SPLEEN; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROCHEMOTHERAPY; ELECTROPORATION; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SPLEEN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33750474876     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20435     Document Type: Article

References (27)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics 2005. CA Cancer J Clin 2005;55:10-30.
2. Schmid HP, Adolfsson J, Aus G. Active monitoring (deferred treatment or watchful waiting) in the treatment of prostate cancer. Eur Urol 2001;40:488-494.
3. Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, Bogdanowicz JF, Van Der Kwast TH, Schroder FH, Mickisch GH. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 2001;165:130-135.
4. Rosemberg Y, Korenstein R. Incorporation of macromolecules into cells and vesicles by low electric fields: Induction of endocytotic-like processes. Bioelectrochem Bioenerg 1997;42:275-281.
5. Antov Y, Barbul A, Korenstein R. Electroendocytosis: Stimulation of adsorptive and fluid-phase uptake by pulsed low electric fields. Exp Cell Res 2004;297:348-362.
6. Antov Y, Barbul A, Mantsur H, Korenstein R. Electroendocytosis: Exposure of cells to pulsed low electric fields enhances adsorption and uptake of macromolecules. Biophys J 2005;88:2206-2223.
7. Entin I, Plotnikov A, Korenstein R, Keisary Y. Tumor growth retardation, cure, and induction of anti tumor immunity in B16 melanoma bearing mice by low electric field enhanced chemotherapy. Clin Cancer Res 2003;9:3190-3197.
8. Plotnikov A, Fishman D, Tichler T, Korenstein R, Keisari Y. Low electric field enhanced chemotherapy can cure mice with CT-26 colon carcinoma and induce anti tumor immunity. Clin Exp Immunol 2004;138:410-416.
9. Plotnikov A, Tichler T, Korenstein R, Keisari Y. Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field enhanced chemotherapy. Int J Cancer 2005;117:816-824.
10. Greenberg N, DeMayo F, Finegolg M, Medina D, Tilley W, Aspinall J, Cunha G, Donjacour A, Matusik R, Rosen J. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92:3439-3443.
11. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
12. Foster B, Gingrich J, Kwon E, Madias C, Greenberg N. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-3330.
13. Gingrich J, Barrios R, Morton R, Boyce B, DeMayo F, Finegold M, Angelopoulou R, Rosen J, Greenberg N. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
14. Haskell CM, Rosen L. Principles of cancer chemotherapy. In: Haskell CM, editor. Cancer treatment, 5th edition, W.B. Philadelphia: Saunders Co; 2001. 140p.
15. Leewansangtong S, Crawford ED. Principles of cancer chemotherapy. In: Haskell C.M. editor. Cancer treatment, 5th edition, Philadelphia: W.B. Saunders Co; 2001. 822p.
16. van Brussel JP, Mickisch GH. Multidrug resistance in prostate cancer. Onkologie 2003;26:175-181.
17. Regev R, Eytan GD. Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem Pharmacol 1997;54:1151-1158.
18. Regev R, Yeheskely-Hayon D, Katzir H, Eytan GD. Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism. Biochem Pharmacol 2005;70:161-169.
19. Sauer H, Putz V, Fischer K, Hescheler J, and Wartenberg M. Increased doxorubicin uptake and toxicity in multicellular tumour spheroids treated with DC electrical fields. Br J Cancer 1999;80:1204-1213.
20. Grossman M. Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines. World J Urol 2001;19:365-370.
21. Gu Z, Thomas G, Yamashiro J, Shintaku I, Dorey F, Raitano A, Witte O, Said J, Loda M, Reiter R. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19:1288-1296.
22. Hara N, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K, Tomita Y. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: Value for the staging of prostate cancer. Clin Cancer Res 2002;8:1794-1799.
23. Altwein J, Luboldt H. Prognostic factors for carcinoma of the prostate. Urol Int 1999;63:62-71.
24. Gaiger A, Reese V, Disis M, Cheever M. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000;96:1480-1489.
25. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997;94:8099-8103.
26. Kraal G, Rep M, Janse M. Macrophages in T and B cell compartments and other tissue macrophages recognized by monoclonal antibody MOMA-2. An immuno-histochemical study. Scand J Immunol 1987;26:653-661.
27. Kanariou M, Huby R, Ladyman H, Colic M, Sivolapenko G, Lampert I, Ritter M. Immunosuppression with cyclosporin A alters the thymic microenvironment. Clin Exp Immunol 1989;78:263-270.